Report
EUR 12.92 For Business Accounts Only

An unfavourable environment weighs on NEXTGEN HEALTHCARE, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of NEXTGEN HEALTHCARE (US), active in the Software industry. As regards its fundamental valuation, the title still shows 2 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date January 18, 2022, the closing price was USD 18.46 and its target price was estimated at USD 14.43.
Underlying
NextGen Healthcare Inc.

NextGen Healthcare is provider of ambulatory-focused healthcare software and services solutions. The company's products and services include: NextGen? Enterprise electronic health records (EHR), which stores and maintains clinical patient information; NextGen? Enterprise practice management (PM), which is a multi-module solution that includes a master patient index, enterprise-wide appointment scheduling with referral tracking, and clinical support; NextGen? Office, which is a cloud-based EHR and PM solution for physicians and medical billing services; and NextGen? Mobile, which enables physicians and other caregivers to create relevant documentation within the EHR.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch